The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Jan. 26, 5:56 AM

Slide #12. Bionano Genomics, Inc. Secondary Offering

Company: Bionano Genomics, Inc. (NASDAQ:BNGO)
Date announced: 1/19/2021
Shares Offered: 33,333,350
Date of Pricing: 1/20/2021
Price Per Share: $6.00
Secondary Offering Details: Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Bionano also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering, to cover over-allotments, if any. All of the shares in the proposed offering are to be sold by Bionano. -updated 1/20- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 33,333,350 shares of its common stock at a price to the public of $6.00 per share. The gross proceeds to Bionano from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $200 million. In addition, Bionano has granted the underwriters a 30-day option to purchase up to an additional 5,000,002 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares in the offering are to be sold by Bionano. The offering is expected to close on January 22, 2021, subject to customary closing conditions.

Bionano Genomics is a life sciences instrumentation company in the genome analysis space. Co. develops and markets the Saphyr system, a platform for structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Co.'s commercial offering includes the Saphyr system, which is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs.
Open the BNGO Page at The Online Investor »

Company Name:  BioNano Genomics Inc
Website:  www.bionanogenomics.com
Sector:  Medical Instruments & Supplies
Number of ETFs Holding BNGO:  1
Total Market Value Held by ETFs:  $58.06M
Total Market Capitalization:  $1.27B
% of Market Cap. Held by ETFs:  4.58%
 

Open the BNGO Page at The Online Investor (in a new window) »

January 26, 2021    5:56 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.50 out of 4)
61st percentile
(ranked higher than approx. 61% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2021, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.